eribulin mesylate (Halaven)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

What is eribulin mesylate, Halaven, and how does it work (mechanism of action)?

Eribulin mesylate is a chemotherapeutic medicine approved to treat metastatic breast cancer, an advanced form of breast cancer that has spread to other parts of the body.

Microtubules are dynamic intracellular structures that are responsible for various kinds of movements including cell division, organization of intracellular structure, and intracellular transport. Eribulin inhibits the growth phase of microtubules, consequently interfering with cell growth and function and eventually causing cancer cell death. Eribulin was developed from a chemical first isolated from the rare marine sponge, Halichondria okadai.

Eribulin can help some patients with metastatic breast cancer live longer. In one trial, women treated with eribulin lived about 2.5 months longer than women who received other treatments. Eribulin was approved by the FDA in 2010.

What brand names are available for eribulin mesylate, Halaven?

Halaven

Is eribulin mesylate, Halaven available as a generic drug?

GENERIC AVAILABLE: No

Do I need a prescription for eribulin mesylate, Halaven?

Yes

What are the side effects of eribulin mesylate, Halaven?

The most common side effects of eribulin are:

The most common serious side effect is decreased white blood cell counts or neutropenia. White blood cells are necessary to fight infections; therefore, significantly low levels of white blood cells may increase the risk for serious infections that can lead to hospitalization or death.

Peripheral neuropathy (damage to the nerves of the extremities) is the most common side effect that causes patients to stop taking eribulin. Severe peripheral neuropathy occurred in 8% of patients treated with eribulin. Furthermore, 5% of patients experienced neuropathy lasting more than 1 year, while 22% of patients developed new or worsening neuropathy that did not get better after an average of 269 days.

Eribulin also can cause abnormalities in the electrocardiogram such as QT prolongation and changes in the heartbeat rhythm that can potentially cause death.

Eribulin can damage the kidney or liver. Risk for injury is higher in patients who have pre-existing kidney or liver disease. To avoid serious injury, such patients should be treated with a lower dose of eribulin.

Quick GuideBreast Cancer Diagnosis and Treatment

Breast Cancer Diagnosis and Treatment
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Cancer Report Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors